|  |
| --- |
| MC 6.01 AST-GN95 Susceptibility Reporting Guidelines |
| **Purpose** | This procedure provides instruction and guidance for routine testing and reporting of Antimicrobial Agents / organism groupings for the AST-GN95 Vitek card for patient testing. Organisms with intrinsic resistance to antimicrobial agents will not be reported. AST-GN95 card will not be used for ***Stenotrophomonas maltophilia*** and ***Burkholderia cepacia*** ***complex.*** |
| **Principal and Clinical Significance** | The decisions for the most appropriate antimicrobial agents to test and report are made with input from Pharmacy, Infectious Disease and the Clinical Laboratory. The goal is to provide clinically relevant information that will decrease the chance of developing antibiotic resistance, harmful effects of inappropriate antimicrobial use and avoid reporting results that could adversely affect patient care. |
| **Policy Statements** | This procedure applies to Microbiologists who perform culture set-up and plate reading. |
| **Special Safety Precautions** | Microbiologists are subject to occupational risks associated with specimen handling.1. [*Biohazard Containment*](file:///G%3A%5CLab%20Procedures%5CMicrobiology%5C1NEW%20Micro%20Procedure%20Manual.%20%28same%20as%20in%20Starnet%29%5CMCVI%203%20Safety%5CMCVI%203.1%20Biohazard%20Containment.docx)
2. [*Biohazardous Spills*](file:///G%3A%5CLab%20Procedures%5CMicrobiology%5C1NEW%20Micro%20Procedure%20Manual.%20%28same%20as%20in%20Starnet%29%5CMCVI%203%20Safety%5CMCVI%203.4%20Biohazardous%20Spills.docx)
3. [*Safety in the Microbiology Laboratory*](file:///G%3A%5CLab%20Procedures%5CMicrobiology%5C1NEW%20Micro%20Procedure%20Manual.%20%28same%20as%20in%20Starnet%29%5CMCVI%203%20Safety%5CMCVI%203.2%20Safety%20in%20the%20Microbiology%20Lab.docx)
 |
|  |  |  |  |  |
| **Procedure** | 1. The AST-GN95 card follows CLSI guidelines and breakpoints.
2. Perform and report KB or MicroScan results for antimicrobial agents that have a card

limitation for patient testing following organism tables below. |
| **Product Limitations** |

|  |  |
| --- | --- |
| Antibiotic | Product Limitations |
| Ampicillin | *Citrobacter spp, Enterobacter spp, Pantoea spp, Serratia spp* and *Cronobacter sakazakii* are intrinsically resistant, Do not report. |
| Ampicillin/Sulbactam | *Citrobacter spp, Enterobacter spp, Pantoea spp, Serratia spp* and *Cronobacter sakazakii* are intrinsically resistant, Do not report. |
| Cefazolin | **Report only on *E.coli, K. pneumoniae, P. mirabilis* from** **urine**Perform KB on all other organisms unless intrinsically resistant, refer to CLSI chart for intrinsic resistance.Perform KB on non-urine sources |
| Cefepime | Perform KB on *Morganella spp* and *Hafnia alvei*Do not report on *Bordetella bronchiseptica* |
| Ceftazidime |  |
| Ceftriaxone | Perform alternate method on *Proteus vulgaris, Enterobacter cloacae, Enterobacter cloacae complex, and Morganella spp.*Perform alternate methodon *Providencia rettgeri* if resistant |
| Ciprofloxacin |  |
| Ertapenem | Perform alternate method with MIC of 0.25-0.5Perform alternate method on *Hafnia alvei* |
| ESBL |  |
| Gentamicin |  |
| Imipenem | Perform alternate method on *Serratia marcescens*Perform KB on *Aeromonas spp.* if resistant |
| Nitrofurantoin (urine) |  |
| Levofloxacin |  |
| Piperacillin /Tazobactam | Perform alternate method on *Serratia marcescens*Perform KB on *P. aeruginosa* if resistant |
| Tobramycin |  |
| Trimeth/Sulfa |   |

Table 1For Non-Enterobacteriaceae, perform MicroScan if alternate method is required. There are no CLSI guidelines for KB with Non-Enterobacteriaceae. |
| **References** | Vitek AST-GN95 Gram Negative Susceptibility Card bioMerieux 2017/11CLSI M100 edition 29 Performance Standards for Antimicrobial Susceptibility Testing 1/2019 |
| **Training Plan/ Competency Assessment** | **Training Plan** | **Initial Competency Assessment** |
| 1. Employee must read the procedure.
2. Employee will observe trainer performing the procedure.
3. Employee will demonstrate the ability to perform procedure, record results and document corrective action after instruction by the trainer.
 | 1. Direct observation.
 |
|  |  |
| **Historical Record** |  |  |  |  |
|  | **Version** | **Written/Revised by:** | **Effective Date:** | **Summary of Revisions** |
| 1 | Susan DeMeyere | 11/5/2019 | Initial version |
| 2 | Susan DeMeyere | 12/6/2019 | Organized product limitation tables. Removed PSAR lower breakpoint validation. |
| 3 | Susan DeMeyere | 1/26/2021 | Removed Validation for lower breakpoint section. Removed validation for Ertapenem.  |
|  |  |  |  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |